JP2014166964A - フィラグリン発現促進剤およびそれを用いた化粧品、皮膚外用剤 - Google Patents
フィラグリン発現促進剤およびそれを用いた化粧品、皮膚外用剤 Download PDFInfo
- Publication number
- JP2014166964A JP2014166964A JP2013039015A JP2013039015A JP2014166964A JP 2014166964 A JP2014166964 A JP 2014166964A JP 2013039015 A JP2013039015 A JP 2013039015A JP 2013039015 A JP2013039015 A JP 2013039015A JP 2014166964 A JP2014166964 A JP 2014166964A
- Authority
- JP
- Japan
- Prior art keywords
- tocopherol
- filaggrin
- expression promoter
- expression
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100028314 Filaggrin Human genes 0.000 title claims abstract description 45
- 101710088660 Filaggrin Proteins 0.000 title claims abstract description 45
- 239000002537 cosmetic Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 37
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 35
- 229960000984 tocofersolan Drugs 0.000 claims abstract description 22
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims abstract description 21
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims abstract description 21
- 239000011732 tocopherol Substances 0.000 claims abstract description 14
- 229930003799 tocopherol Natural products 0.000 claims abstract description 14
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 13
- 229960001295 tocopherol Drugs 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 15
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 15
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 15
- 229940042585 tocopherol acetate Drugs 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 210000003491 skin Anatomy 0.000 description 18
- 210000000434 stratum corneum Anatomy 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 12
- 108700041153 Filaggrin Proteins Proteins 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 4
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 102000000536 PPAR gamma Human genes 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 231100000951 LabCyte EPI-MODEL Toxicity 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 102100030944 Protein-glutamine gamma-glutamyltransferase K Human genes 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- UDGKKUWYNITJRX-UHFFFAOYSA-N davidigenin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=CC=C(O)C=C1O UDGKKUWYNITJRX-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108010058734 transglutaminase 1 Proteins 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 102000030789 Histidine Ammonia-Lyase Human genes 0.000 description 1
- 108700006308 Histidine ammonia-lyases Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 239000009724 Salvia extract Substances 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000005549 barrier dysfunction Effects 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940105902 mint extract Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010330 ougon Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000037330 wrinkle prevention Effects 0.000 description 1
- ONSIBMFFLJKTPT-UHFFFAOYSA-L zinc;2,3,4,5,6-pentachlorobenzenethiolate Chemical compound [Zn+2].[S-]C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl.[S-]C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl ONSIBMFFLJKTPT-UHFFFAOYSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】トコフェロールを有効成分として含有するフィラグリン発現促進剤。本発明のフィラグリン発現促進剤において、トコフェロールがdl−α−トコフェロールまたは酢酸dl−α−トコフェロールであることが好ましく、その含有量は1〜3%であることが好ましい。また本発明は、本発明のフィラグリン発現促進剤を含む化粧品、皮膚外用剤についても提供する。
【選択図】なし
Description
〔1〕フィラグリン蛋白の発現
ヒト三次元培養表皮LabCyte EPI−MODEL(株式会社ジャパン・ティッシュ・エンジニアリング製)にアッセイ培地(株式会社ジャパン・ティッシュ・エンジニアリング製)を添加して培養後、1%、2%または3%の濃度のdl−α−トコフェロールを添加し、培養した。dl−α−トコフェロール添加後の表皮モデルを3、6時間後に回収し、ホルマリン固定、パラフィン包埋後、4μmの組織切片を作製した。その組織切片を、抗ヒトfilaggrin mAb−IgGマウス抗体(一次抗体)(Abcam製)、ペルオキシダーゼ標識抗マウスIgG/HRP抗体(二次抗体)(Dako製)で処理し、フィラグリン蛋白の免疫染色を実施した。組織像は、高感度CCDカメラにて撮影し、フィラグリン蛋白発現は解析ソフトを用いて計測した。
ヒト三次元培養表皮LabCyte EPI−MODEL(株式会社ジャパン・ティッシュ・エンジニアリング製)にアッセイ培地(株式会社ジャパン・ティッシュ・エンジニアリング製)を添加して培養後、2%の濃度の酢酸dl−α−トコフェロールを添加し、培養した。酢酸dl−α−トコフェロール添加後の表皮モデルを3、6時間後に回収し、ホルマリン固定、パラフィン包埋後、4μmの組織切片を作製した。その組織切片を、抗ヒトfilaggrin mAb−IgGマウス抗体(一次抗体)(Abcam製)、ペルオキシダーゼ標識抗マウスIgG/HRP抗体(二次抗体)(Dako製)で処理し、フィラグリン蛋白の免疫染色を実施した。組織像は、高感度CCDカメラにて撮影し、フィラグリン蛋白発現は解析ソフトを用いて計測した。
Claims (5)
- トコフェロールを有効成分として含有するフィラグリン発現促進剤。
- トコフェロールがdl−α−トコフェロールおよび酢酸dl−α−トコフェロールから選ばれる少なくとも1種である、請求項1に記載のフィラグリン発現促進剤。
- dl−α−トコフェロールおよび酢酸dl−α−トコフェロールから選ばれる少なくとも1種の含有量が1〜3%である、請求項1または2に記載のフィラグリン発現促進剤。
- 請求項1〜3のいずれかに記載のフィラグリン発現促進剤を含む、化粧品。
- 請求項1〜3のいずれかに記載のフィラグリン発現促進剤を含む、皮膚外用剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013039015A JP6387220B2 (ja) | 2013-02-28 | 2013-02-28 | フィラグリン発現促進剤およびそれを用いた化粧品、皮膚外用剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013039015A JP6387220B2 (ja) | 2013-02-28 | 2013-02-28 | フィラグリン発現促進剤およびそれを用いた化粧品、皮膚外用剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014166964A true JP2014166964A (ja) | 2014-09-11 |
JP6387220B2 JP6387220B2 (ja) | 2018-09-05 |
Family
ID=51616874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013039015A Active JP6387220B2 (ja) | 2013-02-28 | 2013-02-28 | フィラグリン発現促進剤およびそれを用いた化粧品、皮膚外用剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6387220B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7076695B2 (ja) | 2015-08-12 | 2022-05-30 | 株式会社セレーネ | D-プシコースを有効成分とする皮膚機能改善組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002053127A1 (fr) * | 2000-12-28 | 2002-07-11 | Shiseido Company, Ltd. | Agents d'inhibition ou de reparation d'affections cutanees causees par la secheresse, et procede d'evaluation de celles-ci |
JP2003146886A (ja) * | 2001-11-14 | 2003-05-21 | Noevir Co Ltd | フィラグリン合成促進剤、及び角質層保湿機能改善剤,角質層柔軟化剤,角質層遊離アミノ酸増加剤 |
JP2010184908A (ja) * | 2009-02-13 | 2010-08-26 | Kose Corp | 乳化組成物およびそれを配合する化粧料、並びに皮膚外用剤 |
-
2013
- 2013-02-28 JP JP2013039015A patent/JP6387220B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002053127A1 (fr) * | 2000-12-28 | 2002-07-11 | Shiseido Company, Ltd. | Agents d'inhibition ou de reparation d'affections cutanees causees par la secheresse, et procede d'evaluation de celles-ci |
JP2003146886A (ja) * | 2001-11-14 | 2003-05-21 | Noevir Co Ltd | フィラグリン合成促進剤、及び角質層保湿機能改善剤,角質層柔軟化剤,角質層遊離アミノ酸増加剤 |
JP2010184908A (ja) * | 2009-02-13 | 2010-08-26 | Kose Corp | 乳化組成物およびそれを配合する化粧料、並びに皮膚外用剤 |
Non-Patent Citations (1)
Title |
---|
フレグランスジャーナル臨時増刊 NO.15, JPN6016047216, 1 March 1996 (1996-03-01), pages 169 - 178, ISSN: 0003469405 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7076695B2 (ja) | 2015-08-12 | 2022-05-30 | 株式会社セレーネ | D-プシコースを有効成分とする皮膚機能改善組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP6387220B2 (ja) | 2018-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5312795B2 (ja) | 肌の状態と外観を改善するための組成物及びその使用方法 | |
JP5511284B2 (ja) | 不活性型潜在型TGFbの活性型TGFbへの変換を誘導できる有効成分 | |
JP2021519774A (ja) | 皮膚の処置におけるレチノールの代替 | |
JP5872158B2 (ja) | 皮膚美白方法、並びに、皮膚シミ形成抑制及び/又は除去因子のスクリーニング方法 | |
US20070104810A1 (en) | Agents for sequestering aging factors and uses thereof | |
WO2016015536A1 (en) | Applications of surfactin in cosmetic products and thereof | |
JP7564568B2 (ja) | 皮膚用組成物 | |
US10092495B2 (en) | Use of a composition comprising avocado perseose in the protection of epidermal stem cells | |
BRPI0517829B1 (pt) | composição cosmética tópica compreendendo um extrato vegetal etanólico e um veículo, bem como métodos cosméticos para tratar perda de gordura subcutânea e para melhorar a aparência estética da pele | |
EP2618808B1 (fr) | Utilisation cosmétique de la dermcidine ou fragments de celle-ci | |
JP2015028036A (ja) | Loxタンパク質とnrageタンパク質との通常の共発現と相互作用を復元させる物質 | |
JP2004515523A (ja) | 皮膚の老化の兆候を予防するための、少なくとも一のサポゲニン、またはこれを含有する天然抽出物の使用 | |
CA2909573A1 (fr) | Utilisation de biomarqueurs de la barriere pour l'evaluation de l'efficacite d'actifs | |
WO2016121962A1 (ja) | メラニン産生抑制剤 | |
JP6387220B2 (ja) | フィラグリン発現促進剤およびそれを用いた化粧品、皮膚外用剤 | |
EP2992328B1 (en) | Method of screening for candidate compounds for regulating melanogenesis or pigmentation | |
JP2009242333A (ja) | ペルオキシソーム増殖剤応答性受容体活性化剤、及びそのペルオキシソーム増殖剤応答性受容体活性化剤を配合した皮膚外用剤、化粧料、医薬部外品、飲食品 | |
Oh et al. | A study of anti‐wrinkle functions and improvement of cream with Phaseolus angularis | |
JP2014080409A (ja) | ツバキ属植物エキスを含有する抗炎症剤 | |
JP2023504461A (ja) | 化粧品および医薬品に使用するためのペプチドおよび組成物 | |
US20240099950A1 (en) | Cosmetic compositions and methods of use thereof | |
JP2005350436A (ja) | 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導 | |
EP4135735A1 (fr) | Principe actif comprenant un extrait d'écorce de fruit immature de punica granatum et utilisations pour prevenir et/ou lutter contre l'acne | |
JP6129544B2 (ja) | Sparc産生促進剤 | |
CA2832686C (fr) | Composes activateurs des peptidyl-arginine desiminases 1 et/ou 3 dans l'epiderme et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151229 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170228 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170711 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171010 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20171017 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20171102 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180813 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6387220 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |